PT - JOURNAL ARTICLE AU - Sean, Monica AU - Little, Graham AU - Bautin, Paul AU - Martel, Marylie AU - Descoteaux, Maxime AU - Léonard, Guillaume AU - Tétreault, Pascal TI - What has brain diffusion MRI taught us on chronic pain: a critical review AID - 10.1101/2023.03.03.23286579 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.03.23286579 4099 - http://medrxiv.org/content/early/2023/03/06/2023.03.03.23286579.short 4100 - http://medrxiv.org/content/early/2023/03/06/2023.03.03.23286579.full AB - Chronic pain is a widespread health condition affecting millions of individuals worldwide. Despite its high prevalence, the underlying neural mechanisms and pathophysiology of chronic pain are still not well understood. Introduced about 35 years ago, brain diffusion MRI has emerged as a powerful tool to investigate white matter microstructure and connectivity changes in chronic pain conditions. In this review, we provide an overview of the current state of research on brain diffusion MRI in chronic pain, including the methods used to acquire and analyze diffusion MRI data, as well as the major findings in the field.We discuss the evidence supporting the role of altered white matter microstructure and connectivity in chronic pain conditions, highlighting the importance of studying multiple chronic pain syndromes to identify common neurobiological pathways. We also explore the potential clinical applications of diffusion MRI in chronic pain research, such as identifying biomarkers for diagnosis and treatment response.In addition, we explore the shortcomings and difficulties associated with brain diffusion MRI in chronic pain studies, such as the necessity for uniformity in data acquisition and analysis methods. Finally, we discuss emerging techniques and future directions in brain diffusion MRI research that may provide new insights into the pathophysiology of chronic pain and potential new therapeutic targets. In summary, we are optimistic that brain diffusion MRI has significant potential in furthering our knowledge of chronic pain and enhancing clinical outcomes, although further research is required due to the limited body of literature currently available, and that targeted therapeutic strategies are yet to be identified.Competing Interest StatementMD is co-founder of IMEKA inc. All other authors declare no conflict of interest.Funding StatementMS is supported by a PhD scholarship from the CIHR. GLi is supported by FRQS UNIQUE postdoctoral scholarship. PT is supported by FRQS J1 salary award and Arthritis Society star career development award. GLe is supported by FRQS J2 salary award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript